Abstract: CD146 has been regarded as a novel potential therapeutic target for multiple cancers. The aim of the study was to investigate the expression of CD146 in gastric cancer and evaluate its clinical-pathological and prognostic significance. The expression of CD146 and three epithelial-mesenchymal transition (EMT)-related proteins (E-cadherin, β-catenin and vimentin) was examined in 144 gastric cancers by immunohistochemistry. Fifty-nine cases (41.0%) were defined as positive for CD146 expression. We found that CD146 expression correlated positively with lymph node involvement and a poor prognosis, and retained an independent prognostic factor for gastric cancer patients. Furthermore, positive expression of CD146 was strongly associated with loss of the epithelial marker E-cadherin and acquisition of the expression of the mesenchymal markers nuclear β-catenin and vimentin. These findings suggest that CD146 might promote EMT and progression in gastric cancer, and thus may be a potential therapeutic target for patients with gastric cancers.
This is an open access article distributed under the
Creative Commons Attribution License which permits unrestricted use, distribution,
and reproduction in any medium, provided the original work is properly cited.
Export to BibTeX
MDPI and ACS Style
Liu, W.-F.; Ji, S.-R.; Sun, J.-J.; Zhang, Y.; Liu, Z.-Y.; Liang, A.-B.; Zeng, H.-Z. CD146 Expression Correlates with Epithelial-Mesenchymal Transition Markers and a Poor Prognosis in Gastric Cancer. Int. J. Mol. Sci. 2012, 13, 6399-6406.
Liu W-F, Ji S-R, Sun J-J, Zhang Y, Liu Z-Y, Liang A-B, Zeng H-Z. CD146 Expression Correlates with Epithelial-Mesenchymal Transition Markers and a Poor Prognosis in Gastric Cancer. International Journal of Molecular Sciences. 2012; 13(5):6399-6406.
Liu, Wen-Fang; Ji, Shu-Rong; Sun, Jian-Jun; Zhang, Yi; Liu, Zhong-Yan; Liang, Ai-Bin; Zeng, Hua-Zong. 2012. "CD146 Expression Correlates with Epithelial-Mesenchymal Transition Markers and a Poor Prognosis in Gastric Cancer." Int. J. Mol. Sci. 13, no. 5: 6399-6406.